Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab

INTRODUCTION: Anti-disialoganglioside 2 (anti-GD2) monoclonal antibodies (mAbs) are associated with Grade ≥3 (≥G3) adverse events (AEs) such as severe pain, hypotension, and bronchospasm. We developed a novel method of administering the GD2-binding mAb naxitamab, termed “Step-Up” infusion (STU), to...

Descripción completa

Detalles Bibliográficos
Autores principales: Varo, Amalia, Castañeda, Alicia, Chamorro, Saray, Muñoz, Juan Pablo, Gorostegui, Maite, Celma, Mónica S., Lopez, Sandra, Simao, Margarida, Perez-Jaume, Sara, Mora, Jaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196122/
https://www.ncbi.nlm.nih.gov/pubmed/37213300
http://dx.doi.org/10.3389/fonc.2023.1164949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196122/
https://www.ncbi.nlm.nih.gov/pubmed/37213300
http://dx.doi.org/10.3389/fonc.2023.1164949

Ejemplares similares